Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

Phase 1 Completed 69 enrolled Almirall, S.A.

RandomizedSequentialDouble-blindTreatment

Summary

The main purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity of LAD191 in healthy adults and in adults with an autoimmune disease.

Timeline

Start: 2022-07-29
Primary completion: 2025-04-03
Completion: 2025-04-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LAD191	Unknown	—	Subcutaneous

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

Summary

Timeline

Drugs

Indications